Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma Group has announced a streamlining of its board, with long-serving chair Frank Condella retiring effective 14 January 2026 and non-executive directors Patrick Blake and Anne Lockwood set to step down following the release of the company’s half-year results in February 2026. Professor Bruce Robinson, a non-executive director since 2014 with extensive governance and healthcare sector experience, has been appointed non-executive chair, while the board continues to review its composition to ensure it has the skills and expertise needed to drive shareholder value; the company has also recommended shareholders support the re-election of directors Ann Custin and David Petrie at the upcoming annual general meeting.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group is an ASX-listed specialty pharmaceutical company that commercialises novel medicines with a focus on delivering safer and more accessible treatments. The company is a leader in dermatology and women’s health in the United States and also provides contract development and manufacturing services globally, leveraging a 40-year track record in oral drug delivery technologies.
Average Trading Volume: 568,513
Technical Sentiment Signal: Sell
Current Market Cap: A$257.5M
Learn more about MYX stock on TipRanks’ Stock Analysis page.